隶属于 UCB PHARMA SA
Belgian multinational biopharmaceutical company headquartered in Brussels, focused on research and development of medications for epilepsy, Parkinson's disease, Crohn's disease, and other conditions.
相关临床试验
270
0 进行中
药物批准
137
批准总数
监管机构
5
监管机构数
成立时间
1928
已完成
247
91.5%
终止
17
6.3%
撤回
6
2.2%
- ReAlta Life Sciences appointed Jonathan Rigby, a seasoned biotech executive with a track record of raising over $150 million and leading companies through IPOs and strategic exits, to its Board of Directors. - Rigby brings extensive experience from leadership roles at companies including Zogenix (acquired by UCB Pharma for $2 billion) and SteadyMed Therapeutics (acquired by United Therapeutics for $350 million). - The appointment comes as ReAlta advances pegtarazimod, a dual-mechanism peptide targeting neutrophil-driven inflammation and complement activation for treating conditions like Hypoxic Ischemic Encephalopathy in newborns. - Pegtarazimod has received multiple FDA and EMA designations including Orphan Drug and Fast Track status for Hypoxic Ischemic Encephalopathy and acute Graft vs Host Disease.
- A new comprehensive report analyzes the global clinical trials landscape for Lennox-Gastaut Syndrome, providing critical data on trial numbers, enrollment figures, and regional distribution across G7 and E7 nations. - The analysis covers diverse aspects of clinical trials categorized by region, trial phase, status, sponsorship type, and endpoint analysis, highlighting prominent drugs currently under investigation. - Major pharmaceutical companies including Jazz Pharmaceuticals, Takeda, UCB, GSK, and Eisai are actively conducting trials in this rare epilepsy syndrome space. - The report aims to facilitate strategic business planning and investment decisions while identifying optimal locations for conducting efficient clinical trials in this challenging therapeutic area.
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
- The injectable drug delivery market is projected to reach $1,139.4 billion by 2029, driven by complex biologics and increased demand for patient self-administration. - Industry leaders from Pfizer, GSK, Sandoz, and other major pharmaceutical companies will gather at the Injectable Drug Delivery Conference in London on June 24-25, 2025. - The conference agenda focuses on critical challenges including subcutaneous delivery of biologics, large-volume injectables, and sustainable device development. - A separate PODD 2025 conference in Boston will feature pharmaceutical innovation leaders discussing strategic partnerships and drug delivery technology evaluation frameworks.
- The myasthenia gravis market across seven major markets is projected to grow from $6.1 billion in 2024 to $10.3 billion by 2034, representing a 5.3% compound annual growth rate. - Seven late-stage pipeline products including CRD-1, Descartes-08, Imaavy, gefurulimab, inebilizumab, pozelimab + cemdisiran combination therapy, and telitacicept are expected to drive market expansion. - The combination therapy of pozelimab and cemdisiran shows particular promise for treating seronegative myasthenia gravis patients, addressing a significant unmet medical need. - Despite growth potential, generic erosion and biosimilar competition pose barriers, particularly affecting high-grossing disease-modifying therapies that generated an estimated $5 billion in combined sales in 2024.
- The NHS has approved fenfluramine, the first non-cannabis based treatment for Lennox-Gastaut syndrome (LGS), offering new hope for children aged 2 and above with this severe form of epilepsy. - Clinical trials demonstrated that fenfluramine reduces drop seizure frequency by 26.5% on average, with over 25% of patients experiencing a 50% or greater reduction in seizures. - The treatment will be fast-tracked through NHS England's Innovative Medicines Fund, making it available three months earlier for eligible patients who cannot tolerate existing cannabis-based treatments.
- UCB Pharma aims to expand its portfolio in South Korea after securing approvals for Bimzelx (bimekizumab) for plaque psoriasis and Zilbrysq (zilucoplan) for myasthenia gravis. - Fintepla (fenfluramine) is under review for Dravet syndrome and Lennox-Gastaut syndrome, potentially receiving expedited approval via the GIFT program. - Rystiggo (rozanolixizumab), a monoclonal antibody for myasthenia gravis, may also see accelerated approval if designated under Korea’s GIFT program. - Bimzelx is poised to compete in the plaque psoriasis market, showing superior efficacy in trials against Humira, Stelara, and Cosentyx.
- The FDA has approved bimekizumab (Bimzelx; UCB Pharma) for treating moderate to severe hidradenitis suppurativa in adults, marking its fifth approved indication in the US. - Approval was based on the BE HEARD I and BE HEARD II trials, which demonstrated significant clinical response at week 16 that was sustained through week 48. - Bimekizumab, a monoclonal antibody inhibiting IL-17A and IL-17F, showed greater improvement compared to placebo in reducing abscesses and inflammatory nodules. - The studies' primary endpoint, HiSCR50, was achieved by patients on bimekizumab, offering a new treatment option for this chronic inflammatory skin disorder.
- The FDA has approved bimekizumab-bkzx (Bimzelx) for treating moderate-to-severe hidradenitis suppurativa (HS) in adult patients, addressing a significant unmet clinical need. - Bimekizumab, a humanized IgG1 monoclonal antibody, uniquely targets and inhibits both interleukin (IL)-17A and IL-17F cytokines, providing a more complete blockade of inflammation. - Clinical trials BE HEARD I and BE HEARD II demonstrated that bimekizumab significantly reduced HS symptoms, with many patients achieving a 75% reduction in inflammatory lesions. - Long-term data from an open-label extension study showed continued improvement, with approximately 40% of patients achieving complete clearance of abscesses and inflammatory nodules.
• Bepranemab, a monoclonal antibody from UCB Pharma, is the first to demonstrate a slowing of tau tangle accumulation in Alzheimer's patients, marking a potential shift in treatment strategies. • Phase 2 trial data suggests cognitive benefits in a subgroup with low baseline tau levels and without the ApoE4 mutation, indicating a targeted approach may be necessary for efficacy. • The trial results support the hypothesis that extracellular tau 'seeds' drive Alzheimer's progression, opening avenues for understanding disease mechanisms and developing combination therapies. • Several companies are developing antibodies targeting the microtubule binding region (MTBR) of tau, with ongoing trials exploring their impact on tau spread and clinical outcomes.
